# Task Order 4: Nonclinical Toxicology Study of an Investigational Agent in Development for Anticancer Therapy

> **NIH NIH N01** · SRI INTERNATIONAL · 2023 · $1,416

## Abstract

The test agent is being considered for development as an anticancer therapeutic. 
The objective of this task was to characterize the target organ toxicities of an investigative agent that might move forward to clinical testing for anticancer activity. 
The information obtained from this investigation was used to identify drugs with the potential to treat cancer.

## Key facts

- **NIH application ID:** 10867250
- **Project number:** 261201100028C-P00018-9999-2
- **Recipient organization:** SRI INTERNATIONAL
- **Principal Investigator:** TOUFAN PARMAN
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $1,416
- **Award type:** —
- **Project period:** 2011-07-01 → 2016-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10867250

## Citation

> US National Institutes of Health, RePORTER application 10867250, Task Order 4: Nonclinical Toxicology Study of an Investigational Agent in Development for Anticancer Therapy (261201100028C-P00018-9999-2). Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/grant/nih/10867250. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*